Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

T lymphocytes undergo proliferation arrest when exposed to tryptophan shortage, which can be provoked by indoleamine 2,3-dioxygenase (IDO), an enzyme that is expressed in placenta and catalyzes tryptophan degradation. Here we show that most human tumors constitutively express IDO. We also observed that expression of IDO by immunogenic mouse tumor cells prevents their rejection by preimmunized mice. This effect is accompanied by a lack of accumulation of specific T cells at the tumor site and can be partly reverted by systemic treatment of mice with an inhibitor of IDO, in the absence of noticeable toxicity. These results suggest that the efficacy of therapeutic vaccination of cancer patients might be improved by concomitant administration of an IDO inhibitor.

Original publication

DOI

10.1038/nm934

Type

Journal article

Journal

Nat Med

Publication Date

10/2003

Volume

9

Pages

1269 - 1274

Keywords

Animals, CD8-Positive T-Lymphocytes, Cell Line, Tumor, Female, Humans, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mice, Neoplasm Transplantation, Neoplasms, Placenta, Pregnancy, RNA, Messenger, Tryptophan, Tryptophan Oxygenase, Tumor Escape